Image-based assessment of natural killer cell activity against glioblastoma stem cells.
NK cell migration and cytotoxicity
glioblastoma stem cells (GSCs)
image‐based assays
immunotherapy
natural killer (NK) cells
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
revised:
08
04
2024
received:
02
01
2024
accepted:
03
05
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
Glioblastoma (GBM) poses a significant challenge in oncology and stands as the most aggressive form of brain cancer. A primary contributor to its relentless nature is the stem-like cancer cells, called glioblastoma stem cells (GSCs). GSCs have the capacity for self-renewal and tumorigenesis, leading to frequent GBM recurrences and complicating treatment modalities. While natural killer (NK) cells exhibit potential in targeting and eliminating stem-like cancer cells, their efficacy within the GBM microenvironment is limited due to constrained infiltration and function. To address this limitation, novel investigations focusing on boosting NK cell activity against GSCs are imperative. This study presents two streamlined image-based assays assessing NK cell migration and cytotoxicity towards GSCs. It details protocols and explores the strengths and limitations of these methods. These assays could aid in identifying novel targets to enhance NK cell activity towards GSCs, facilitating the development of NK cell-based immunotherapy for improved GBM treatment.
Identifiants
pubmed: 38740554
doi: 10.1002/2211-5463.13818
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30CA030199
Pays : United States
Informations de copyright
© 2024 The Authors. FEBS Open Bio published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
Références
Schaff LR and Mellinghoff IK (2023) Glioblastoma and other primary brain malignancies in adults: a review. JAMA 329, 574–587.
Prager BC, Bhargava S, Mahadev V, Hubert CG and Rich JN (2020) Glioblastoma stem cells: driving resilience through chaos. Trends Cancer 6, 223–235.
Gimple RC, Bhargava S, Dixit D and Rich JN (2019) Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer. Genes Dev 33, 591–609.
Kraus RF and Gruber MA (2021) Neutrophils‐from bone marrow to first‐line defense of the innate immune system. Front Immunol 12, 767175.
Nicholson LB (2016) The immune system. Essays Biochem 60, 275–301.
Yatim KM and Lakkis FG (2015) A brief journey through the immune system. Clin J Am Soc Nephrol 10, 1274–1281.
Lupo KB and Matosevic S (2019) Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy. Cancers (Basel) 11, 769.
Wu SY, Fu T, Jiang YZ and Shao ZM (2020) Natural killer cells in cancer biology and therapy. Mol Cancer 19, 120.
Ames E, Canter RJ, Grossenbacher SK, Mac S, Chen M, Smith RC, Hagino T, Perez‐Cunningham J, Sckisel GD, Urayama S et al. (2015) NK cells preferentially target tumor cells with a cancer stem cell phenotype. J Immunol 195, 4010–4019.
Luna JI, Grossenbacher SK, Murphy WJ and Canter RJ (2017) Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther 17, 313–324.
Balatsoukas A, Rossignoli F and Shah K (2022) NK cells in the brain: implications for brain tumor development and therapy. Trends Mol Med 28, 194–209.
Murad S, Michen S, Becker A, Fussel M, Schackert G, Tonn T, Momburg F and Temme A (2022) NKG2C+ NK cells for immunotherapy of glioblastoma multiforme. Int J Mol Sci 23, 5857.
Breznik B, Ko MW, Tse C, Chen PC, Senjor E, Majc B, Habic A, Angelillis N, Novak M, Zupunski V et al. (2022) Infiltrating natural killer cells bind, lyse and increase chemotherapy efficacy in glioblastoma stem‐like tumorospheres. Commun Biol 5, 436.
Du Y, Pollok KE and Shen J (2023) Unlocking glioblastoma secrets: natural killer cell therapy against cancer stem cells. Cancers (Basel) 15, 5836.
Jung J, Kim LJ, Wang X, Wu Q, Sanvoranart T, Hubert CG, Prager BC, Wallace LC, Jin X, Mack SC et al. (2017) Nicotinamide metabolism regulates glioblastoma stem cell maintenance. JCI Insight 2, e90019.
Wang X, Prager BC, Wu Q, Kim LJY, Gimple RC, Shi Y, Yang K, Morton AR, Zhou W, Zhu Z et al. (2018) Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression. Cell Stem Cell 22, e5.
Qiu Z, Zhao L, Shen JZ, Liang Z, Wu Q, Yang K, Min L, Gimple RC, Yang Q, Bhargava S et al. (2022) Transcription elongation machinery is a Druggable dependency and potentiates immunotherapy in glioblastoma stem cells. Cancer Discov 12, 502–521.
Krouwels IM, Wiesmeijer K, Abraham TE, Molenaar C, Verwoerd NP, Tanke HJ and Dirks RW (2005) A glue for heterochromatin maintenance: stable SUV39H1 binding to heterochromatin is reinforced by the SET domain. J Cell Biol 170, 537–549.
Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC et al. (2021) FBXO44 promotes DNA replication‐coupled repetitive element silencing in cancer cells. Cell 184, e23.
Bratosin D, Mitrofan L, Palii C, Estaquier J and Montreuil J (2005) Novel fluorescence assay using calcein‐AM for the determination of human erythrocyte viability and aging. Cytometry A 66, 78–84.
Chava S, Bugide S, Gupta R and Wajapeyee N (2020) Measurement of natural killer cell‐mediated cytotoxicity and migration in the context of hepatic tumor cells. J Vis Exp doi: 10.3791/60714
Bonanni V, Antonangeli F, Santoni A and Bernardini G (2019) Targeting of CXCR3 improves anti‐myeloma efficacy of adoptively transferred activated natural killer cells. J Immunother Cancer 7, 290.
Bernardini G, Sciume G, Bosisio D, Morrone S, Sozzani S and Santoni A (2008) CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets. Blood 111, 3626–3634.
Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K et al. (2021) Targeting the alphav integrin/TGF‐beta axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131, e142116.
Galat Y, Du Y, Perepitchka M, Li XN, Balyasnikova IV, Tse WT, Dambaeva S, Schneiderman S, Iannaccone PM, Becher O et al. (2023) In vitro vascular differentiation system efficiently produces natural killer cells for cancer immunotherapies. Onco Targets Ther 12, 2240670.